The Investor Relations website contains information about Karyopharm Therapeutics business for stockholders, potential investors, and financial analysts.
http://investors.karyopharm.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
1.8 seconds
16x16
32x32
PAGES IN
THIS WEBSITE
19
SSL
EXTERNAL LINKS
32
SITE IP
206.200.251.19
LOAD TIME
1.844 sec
SCORE
6.2
Karyopharm :: Investors :: Investor Relations | investors.karyopharm.com Reviews
https://investors.karyopharm.com
The Investor Relations website contains information about Karyopharm Therapeutics business for stockholders, potential investors, and financial analysts.
investors.karyopharm.com
Events & Presentations - Karyopharm Therapeutics
http://investors.karyopharm.com/events.cfm
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Annual Reports and Proxies. Investigator Sponsored Trials (IST). Details on upcoming events are not yet available. Please click here. To be notified of all upcoming events. Mar 16, 2017. File is in Briefcase. Apr 5, 2017. 16th Annual Needham Healthcare Conference. Mar 16, 2017. Karyopharm Therapeutics 4Q Conference Call. Feb 16, 2017. Leerink Partners 6th Annual Global Healthcare Conference. Feb 7, 2017. Jan 10, 2017. Dec 5, 2016. LEERINK ...
Investor Relations - Karyopharm Therapeutics
http://investors.karyopharm.com/index.cfm
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Annual Reports and Proxies. Investigator Sponsored Trials (IST). 044 ( 6.89%). Day High: 7.07. Day Low: 6.27. 4:00 PM ET on Nov 4, 2016. Delayed at least 20 minutes. Investor Presentation, September, 2016. Nov 3, 2016. Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting. Nov 3, 2016. View all press releases ». Nov 7, 2016 at 5:00 PM ET. Newton, MA 02459.
Corporate Governance - Karyopharm Therapeutics
http://investors.karyopharm.com/corporate-governance.cfm
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Annual Reports and Proxies. Investigator Sponsored Trials (IST). Ard of Directors of Karyopharm. A Therapeutics (the Company). Sets high standards for the C. Ompanys employees, officers a. Nd directors. Implicit in this. Philosophy is the importance. Of sound corporate governance. It is the duty of the Board o. F Directors to serve as a prud. Ent fiduciary for shareholders. And to oversee the management. Of the Companys business. To.
SEC Filings - Karyopharm Therapeutics
http://investors.karyopharm.com/sec.cfm
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Annual Reports and Proxies. Investigator Sponsored Trials (IST). All Filings (excluding Section 16). Aug 4, 2016. File is in Briefcase. Aug 4, 2016. File is in Briefcase. Jun 27, 2016. File is in Briefcase. Jun 17, 2016. Weg, kenneth e. File is in Briefcase. Jun 17, 2016. File is in Briefcase. Jun 17, 2016. Mirza, mansoor raza. File is in Briefcase. Jun 17, 2016. Greene, barry e. File is in Briefcase. Jun 17, 2016. Garland, j. scott.
Press Releases - Karyopharm Therapeutics
http://investors.karyopharm.com/releases.cfm
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Annual Reports and Proxies. Investigator Sponsored Trials (IST). Aug 4, 2016. Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress. Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to Report Top-Line Data from STORM and STOMP Studies in Relapsed/Refractory Multiple Myeloma and Updated Data from SIGN Study in Gynecologic Malignancies Confere. Aug 3, 2016. Oral ...
TOTAL PAGES IN THIS WEBSITE
19
Overview - Karyopharm Therapeutics
http://karyopharm.com/about
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Events & Presentations. Financial & Filings. Annual Reports & Proxies. Investigator Sponsored Trials (IST). Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development and subsequent commercialization of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Our other drug candidates in development include oral ...
Investigator Sponsored Trials (IST) - Karyopharm Therapeutics
http://karyopharm.com/drug-candidate/investigator-sponsored-trials-ist
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Events & Presentations. Financial & Filings. Annual Reports & Proxies. Investigator Sponsored Trials (IST). Investigator Sponsored Trials (IST). Karyopharm is committed to supporting Investigator Sponsored Trials (ISTs) globally as part of the development process of Selinexor (KPT-330). Support of ISTs may be provided in the form of drug supply only or drug supply with funding. For a preliminary discussion of their research proposal. Oral ...
Posters and Presentations - Karyopharm Therapeutics
http://karyopharm.com/publication/posters-and-presentations
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Events & Presentations. Financial & Filings. Annual Reports & Proxies. Investigator Sponsored Trials (IST). Posters & Presentations. A Phase 1B/2 Study of Selinexor in Combination with Backbone Therapies for Treatment of Relapsed/Refractory Multiple Myeloma. Phase I Trial of the Combination of Selinexor (SEL), Liposomal Doxorubicin (DOX) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM). Selinexor, a Selective Inh...
Careers - Karyopharm Therapeutics
http://karyopharm.com/careers
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Events & Presentations. Financial & Filings. Annual Reports & Proxies. Investigator Sponsored Trials (IST). Director/Senior Director GMP Quality. Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of novel first in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Please check below the job position for which you are applying.
Papers - Karyopharm Therapeutics
http://karyopharm.com/publication/papers
Oral Dual Inhibitor of PAK4. Investigator Sponsored Trials (IST). Events & Presentations. Financial & Filings. Annual Reports & Proxies. Investigator Sponsored Trials (IST). Posters & Presentations. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth. XPO1, therapeutic and prognostic target in sarcomas. Newton, MA 02459.
TOTAL LINKS TO THIS WEBSITE
32
Investor Overview - Joy Global Inc.
HAC and Related Systems. Surface Crushing and Conveying Equipment. Room and Pillar / Entry Development. Underground Crushing and Conveying Equipment. Prognostics and Health Monitoring. Technical and Field Services. Machine Assembly and Rebuilds. Joy Global In the News. 4:02 PM ET on Aug 7, 2015. Delayed at least 20 minutes. Through its market-leading businesses – Joy Global Surface Mining. And Joy Global Underground Mining. You may also be interested in. Learn about our JBS Operational Excellence program.
James River Group : Investor Relations Home
Excess and Surplus Lines. There are currently no events. James River Group Holdings Reports Second Quarter Net Operating Income of $12.4 Million or $0.42 Per Diluted Share. James River Group Holdings, Ltd. Announces Dates for Its 2015 Second Quarter Earnings Release and Conference Call. James River Group Holdings Reports First Quarter Net Operating Income of $11.7 Million or $0.40 Per Diluted Share. 160; 0.36. 08/18/15 11:57 am ET. Minimum 20 minute delay.
Investor Relations | Investor Home | Juhayna
Juhayna is the leading Egyptian producer and distributor of premium dairy, yoghurt, juice and concentrate products. Yoghurt, Cream and Cheese. Try out the newest pure flavor. Enjoy the new flavor of Rayeb. PRESS and MEDIA CENTER. Juhayna Press and Media Center. Juhayna Releases Second Quarter 2015 Earnings. Juhayna and Leading European Dairy Producer Arla Foods Will Form New Joint Venture in Egypt. Juhayna Releases First Quarter 2015 Earnings. Juhanya Announces Dividend Payment. Revenues EGP 3,294 million.
Investor Overview | Investor Relations | K12
Please Update Your Browser. It is recommended that you update your browser to the latest version to view the website's full experience. Find the online public or private school that. Will fit your needs. Please enter a 5-digit zip code. Outside the U.S? K12 Inc. Reports Fiscal 2015 Revenue of $948.3 Million and Operating Income of $18.4 Million. Detailed data on assessment results continues K12’s commitment to accountability and transparency. 160; 0.19. Data as of 08/07/15 4:00 pm ET. Logo and other marks.
Investor Relations | Kaiser Aluminum
Skip to main navigation. Aerospace and High Strength. Leading positions in strategic market segments. Excellent earnings growth potential. Attractive, growing market segments. Platform for additional organic/inorganic growth. Financial strength and flexibility. Kaiser Aluminum Corporation Reports Fourth Quarter and Full Year 2017 Financial Results. Feb 21, 2018. Kaiser Aluminum Announces Fourth Quarter and Full Year 2017 Earnings Release and Conference Call. Feb 01, 2018.
Karyopharm :: Investors :: Investor Relations
Investigator Sponsored Trials (IST). Annual reports and Proxies. Annual Reports and Proxies. Investigator Sponsored Trials (IST). Investor Presentation, August 2015. Aug 10, 2015. Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress. Aug 3, 2015. Karyopharm to Report Second Quarter 2015 Financial Results on August 10, 2015. View all press releases. Aug 12, 2015. 2015 Wedbush PacGrow Healthcare Conference. Aug 10, 2015 at 8:30 AM ET. View all events and presentations.
KBR Inc. - Investors - Investor Overview
Pricing delayed 20 minutes. KBR is a global provider of differentiated professional services and technologies across the asset and program life cycle within the Government Services and Hydrocarbons sectors. KBR employs over 34,000 people worldwide, with customers in more than 80 countries, and operations in 40 countries, across three synergistic global businesses:. Engineering and Construction, including onshore oil and gas; LNG (liquefaction and regasification)/GTL; oil refining; petrochemicals; chemica...
Kcell Investors
Контакты для связи с Инвесторами. 17 июля 2015 года представила отчет о результатах деятельности за январь-июнь 2015 года. Компания объявила о результатах Годового общего собрания акционеров Компании (ГОСA), состоявшегося 17 апреля 2015 года. Выберите RSS-канал из нижеприведённого списка для получения свежей информации об обновлениях для вашего RSS-ридера. Январь - Июнь, 2015. Отчет по результатам за январь-июнь, 2015. Презентация по результатам деятельности за январь-июнь, 2015. АО Кселл 2000 - 2015.
Kellan Group Plc | Kellan Group Plc – AIM listed recruitment business
Unique brands. Shared culture. Kellan Group Plc 2014.
Overview | Investor Relations | Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. SEC Filings and Annual Reports. Q2 2015 Keryx Biopharmaceuticals, Inc. Earnings Conference Call. 160;at 8:00 am ET. Keryx is headquartered in New York City, and recently expanded its footprint to Boston, the country's life sciences hub, to support the US launch of Ferric Citrate. Several functions are housed in the company's Boston office, including commercial, regulatory, medical affairs, as well as many general and administrative functions. 160; 0.58. Keryx Biopharmaceuti...
Investor Relations | KeyW Corporation
Skip to main navigation. Defensive Cyberspace Operations and Training. Cyber Mission Training and Exercises. Cloud and Data Analytics. Data Discovery, Transformation and Analysis. Data Management and Security. Cloud Infrastructure and Engineering. Custom Packaging and Microelectronics. Analysis & Operations. Mar 15, 2018. KeyW Reports Fourth-Quarter and Fiscal Year 2017 Financial Results. Mar 08, 2018. KeyW Announces 2018 Analyst and Investor Day. View all investor press releases. Mar 20, 2018.
SOCIAL ENGAGEMENT